There are 2949 resources available
522TiP - PRODIGE 71 - BEVAMAINT: A randomized phase III study comparing maintenance treatment with fluoropyrimidine + bevacizumab versus fluoropyrimidine after induction chemotherapy for a metastatic colorectal cancer
Presenter: Thomas Aparicio
Session: E-Poster Display
Resources:
Abstract
523TiP - MOUNTAINEER: Open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer
Presenter: John Strickler
Session: E-Poster Display
Resources:
Abstract
538P - Vemurafenib in non-melanoma V600 and non-V600 BRAF mutated cancers: Results of the AcSé basket trial
Presenter: Pascale Tomasini
Session: E-Poster Display
Resources:
Abstract
539P - Patient-reported outcomes (PROs) from patients (Pts) with NTRK fusion-positive (NTRK-fp) solid tumours receiving entrectinib in the global phase II STARTRK-2 study
Presenter: Anthony Conley
Session: E-Poster Display
Resources:
Abstract
540P - Entrectinib in patients with <italic>ROS1</italic> fusion-positive non-small cell lung cancer (NSCLC) or <italic>NTRK</italic> fusion-positive solid tumours: Analysis of response by line of therapy
Presenter: Stephen Liu
Session: E-Poster Display
Resources:
Abstract
541P - Derazantinib (DZB), an oral fibroblast growth factor receptor inhibitor (FGFRi), shows promising activity in PDX-tumour models with aberrations in FGFR1-3
Presenter: Paul Mcsheehy
Session: E-Poster Display
Resources:
Abstract
542P - Growth modulation index (GMI) of larotrectinib versus prior systemic treatments for TRK fusion cancer patients
Presenter: Antoine Italiano
Session: E-Poster Display
Resources:
Abstract
543P - Entrectinib in NTRK fusion-positive NSCLC: Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Alexander Drilon
Session: E-Poster Display
Resources:
Abstract
544P - Phase I study of the irreversible FGFR inhibitor (i) futibatinib (FBN; TAS-120) in Japanese patients (pts) with advanced (adv) solid tumours
Presenter: Chigusa Morizane
Session: E-Poster Display
Resources:
Abstract
545P - Preclinical profile of EPI-7386, a second-generation N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer
Presenter: Ronan Le Moigne
Session: E-Poster Display
Resources:
Abstract